These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 29064851)

  • 1. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
    Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients.
    Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Hashem MB; Hassan EM; Salah A; Omran DA; Elbaz TM
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):75-79. PubMed ID: 30199473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular Carcinoma Occurrence/Recurrence after Direct-Acting Antivirals for Hepatitis C in Egyptian Cohort: Single-Center Experience.
    Lashen SA; Shamseya MM; Madkour MA
    Dig Dis; 2019; 37(6):488-497. PubMed ID: 31216532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C Virus-Related One-Year Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial.
    Kamal A; Metawea M; Omar H; Ghallab M; Kassem A; Naguib H
    J Gastrointest Cancer; 2024 Jun; 55(2):913-923. PubMed ID: 38436921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
    Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
    J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
    World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
    Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
    Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
    Singal AG; Rich NE; Mehta N; Branch A; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Wong R; Huang A; Misra S; Schwartz M; Mitrani R; Nakka S; Noureddine W; Ho C; Konjeti VR; Dao A; Nelson K; Delarosa K; Rahim U; Mavuram M; Xie JJ; Murphy CC; Parikh ND
    Gastroenterology; 2019 May; 156(6):1683-1692.e1. PubMed ID: 30660729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.
    Ochi H; Hiraoka A; Hirooka M; Koizumi Y; Amano M; Azemoto N; Watanabe T; Yoshida O; Tokumoto Y; Mashiba T; Yokota T; Abe M; Michitaka K; Hiasa Y; Joko K
    J Gastroenterol; 2021 Jan; 56(1):90-100. PubMed ID: 33278003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Singal AG; Lim JK; Kanwal F
    Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
    Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
    J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Damned if you do, damned if you don't: The evolving story of de novo and recurrent hepatocellular carcinoma amongst those treated with direct-acting antivirals for hepatitis C virus.
    Yang JD; Leise MD
    Liver Int; 2017 Jun; 37(6):809-811. PubMed ID: 28544691
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
    Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
    J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study.
    Nakano M; Koga H; Ide T; Kuromatsu R; Hashimoto S; Yatsuhashi H; Seike M; Higuchi N; Nakamuta M; Shakado S; Sakisaka S; Miuma S; Nakao K; Yoshimaru Y; Sasaki Y; Oeda S; Eguchi Y; Honma Y; Harada M; Nagata K; Mawatari S; Ido A; Maeshiro T; Matsumoto S; Takami Y; Sohda T; Torimura T
    Cancer Med; 2019 May; 8(5):2646-2653. PubMed ID: 30900818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.
    Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    Aliment Pharmacol Ther; 2018 Jan; 47(1):104-113. PubMed ID: 29035002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.